SLC30A6

Across TCGA pan-cancer cohorts, SLC30A6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC30A6 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SLC30A6 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC30A6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LIHC, and ACC are the cancer types where SLC30A6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.440	.019	22	view →
LIHC	OS	Median	All	0.122	0.704	.009	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	9	view →
SKCM	OS	Median	III,IV	0.175	0.705	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC30A6–UCEC (DFS)

Open the UCEC breakdown →